Publicaciones en colaboración con investigadores/as de University of Auckland (49)

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759

  2. A genome-wide association analysis reveals new pathogenic pathways in gout*

    Nature Genetics

2023

  1. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set

    Seminars in Arthritis and Rheumatism, Vol. 60

  2. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  3. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

2021

  1. Correction to: Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects (Journal of Human Genetics, (2021), 66, 2, (161-169), 10.1038/s10038-020-0821-z)

    Journal of Human Genetics

  2. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

  3. Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects

    Journal of Human Genetics, Vol. 66, Núm. 2, pp. 161-169

  4. Which factors predict discordance between a patient and physician on a gout flare?

    Rheumatology (United Kingdom), Vol. 60, Núm. 2, pp. 773-779

2020

  1. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2544-2549

2019

  1. Combination urate-lowering therapy in the treatment of gout: What is the evidence?

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 4, pp. 658-668

  2. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

    Arthritis Research and Therapy, Vol. 21, Núm. 1

  3. Gout

    Rheumatic Disease Clinics of North America, Vol. 45, Núm. 4, pp. 583-591

  4. Gout

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

  5. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  6. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

2018

  1. Brief Report: Validation of a Definition of Flare in Patients With Established Gout

    Arthritis and Rheumatology, Vol. 70, Núm. 3, pp. 462-467

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150